
|Articles|June 4, 2012
MedPoint Digital Expands Mobile Services for Clinical Trials
Advertisement
- TriPort Clinical Trial Portal—MedPoint has evolved its core clinical portal to span the worlds of desktop and mobile, so it is compatible across devices, operating systems and browsers. TriPort is a secure, fully validated clinical trial technology that delivers study-specific information, training, and communications. TriPort is built for interoperability and supports role-based access to study resources and individual tracking of activity completion.
- TelePoint Virtual Meeting System—The latest TelePoint release is cross-platform compatible, supporting live virtual meetings that simultaneously connect participants from desktop computers, smart phones, and tablets. This proprietary system works across all major operating systems and devices, blurring the lines between conventional web conferencing and app-enabled conferencing.
- ActivMedia Modules—MedPoint has implemented a new mobile-compatible development platform to produce its next generation of multimedia/interactive web modules. Using its ActivMedia platform, MedPoint develops intuitive web modules that engage users for self-learning, real-world simulations, and training certification.
- SFX Site Feasibility Xelerator—With the latest release of the SFX platform, study sites can complete survey forms over their mobile devices, making it faster and easier for sponsors to collect site profile information into a secure workspace for analysis, vetting, and promotion.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Real-Time Trials Need More Than AI: Why Operational Trial Infrastructure Matters
2
FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership
3
ACT Brief: Commercial Strategy Shaping Early Clinical Development, Real-Time Trials Require Operational Infrastructure, and AI Site Engagement Gap
4
ACT Brief: Lean Development Through Fractional Teams and Partners, FDA Expedited IND Pilot for Phase I Acceleration, and Tudriqev Accelerated Approval for Anti-PD-1-Refractory Melanoma
5




